Abstract
In the last two decades, the therapy of multiple myeloma (MM) has changed radically with the possibility to use targeted drugs, such as proteasome inhibitors, immunomodulatory substances and monoclonal antibodies. These products of first, second and third generation in different combinations now comprise the backbone of MM treatment.
Overall survival has increased two-fold in the last decades. However, in most cases, relapses occur and a resistance to therapy gradually develops.
Elotuzumab (Elo) is the first monoclonal antibody in MM approved for clinical practice; in 2015, American Food and Drug Administration has approved it as so called breakthrough therapy. The target antigen is a surface receptor SLAMF7 (also CS1) from CD2 group and SLAMF family (signaling lymphocytic activation molecule).
At the moment, Elo is approved in combination with dexamethasone and either lenalidomide or pomalidomide for relapsing myeloma patients. The advantage of Elo compared with other evaluated antibodies is safety and good tolerance.
Allergic reactions recorded in low numbers by clinical trials are not serious and easily managed.